Monitor for MHRA response in Q4 2026, which could be a near-term catalyst for TRAW. The unresolved FDA clinical hold limits upside; any positive MHRA outcome may not directly resolve the FDA hold. Traders should watch for further updates on the FDA status.
Price Chart
Executive Summary
Traws Pharma announced it will resubmit an updated toxicology data package to the UK MHRA in Q3 2026 for tivoxavir marboxil (TXM) to enable a Phase 2a human influenza challenge study. The MHRA response is expected within 30 days of resubmission. The filing is a procedural regulatory update with no new financial data; the existing FDA clinical hold on TXM remains a key overhang.
Key Facts
- Resubmission of updated toxicology data package to UK MHRA expected in Q3 2026
- MHRA response expected within 30 days of resubmission
- Phase 2a human influenza challenge study for tivoxavir marboxil (TXM) is the planned next step
- FDA clinical hold on TXM remains in place (mentioned in risk factors)
- $12M market cap clinical-stage biotech with no revenue disclosed
Financial Impact
No financial figures provided; regulatory progress may extend cash runway visibility but no quantified impact
Risk Factors
- MHRA could reject or request additional data, delaying the challenge study
- FDA clinical hold on TXM remains unresolved and could materially impact US development
- Low cash runway typical for micro-cap biotech; potential dilution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-076058 |
| Document: tm2618195d1_99-1.htm | 0001104659-26-076058 |
| Document: 0001104659-26-076058-index-headers.html | 0001104659-26-076058 |
| Document: 0001104659-26-076058-index.html | 0001104659-26-076058 |
| Document: 0001104659-26-076058.txt | 0001104659-26-076058 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | S-1 | $0.3500 | awaiting T+20 | — | $0.3400 (+2.86%) |
Oct 23, 2026 3d ago | 8-K | $0.3510 | awaiting T+20 | — | $0.3400 (+3.13%) |
Oct 20, 2026 6d ago | DEFA14A | $0.3760 | awaiting T+20 | — | $0.3400 (−9.57%) |
Oct 20, 2026 6d ago | DEF 14A | $0.3760 | awaiting T+20 | — | $0.3400 (+9.57%) |
Aug 14, 2026 10w ago | Press Release | $0.5400 $0.5200 | ▲ +3.70% | ▲ +2.18% | $0.3400 (+37.04%) |
Jul 10, 2026 15w ago | 8-K | $0.6849 $0.5400 | ▲ +21.16% | ▲ +24.34% | $0.3400 (+50.36%) |
Jul 10, 2026 15w ago | 424B5 | $0.6849 $0.5400 | ▲ +21.16% | ▲ +24.34% | $0.3400 (+50.36%) |
Jul 10, 2026 15w ago | EFFECT | $0.7600 $0.5320 | ▲ +30.00% | ▲ +32.43% | $0.3400 (+55.26%) |
Jul 9, 2026 15w ago | 8-K | $0.7600 $0.5320 | ▼ −30.00% | ▼ −32.43% | $0.3400 (−55.26%) |
Jul 1, 2026 16w ago | S-3 | $0.7677 $0.4411 | ▼ −42.54% | ▼ −42.13% | $0.3400 (−55.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers